Page 88 - Read Online

Aguiar. Rare Dis Orphan Drugs J 2024;3:13 https://dx.doi.org/10.20517/rdodj.2023.56 Page 29 of 29

cardiomyopathy. J Am Heart Assoc 2018;7:e007124. DOI PubMed PMC
246. Aguiar P, Azevedo O, Pinto R, et al. Collagen type I synthesis biomarkers predict the progression of Fabry disease cardiomyopathy.
Mol Genet Metab 2018;123:S16. DOI
247. Hernández-Romero D, Sánchez-Quiñones J, Vílchez JA, et al. Galectin-3 and β-trace protein concentrations are higher in clinically
unaffected patients with Fabry disease. Sci Rep 2019;9:6235. DOI PubMed PMC
248. Riccio E, Sabbatini M, Capuano I, Pisani A. Early biomarkers of Fabry nephropathy: a review of the literature. Nephron
2019;143:274-81. DOI PubMed
249. Fall B, Scott CR, Mauer M, et al. Urinary podocyte loss is increased in patients with Fabry disease and correlates with clinical
severity of fabry nephropathy. PLoS One 2016;11:e0168346. DOI PubMed PMC
250. Pereira EM, Silva AS, Labilloy A, Monte Neto JT, Monte SJ. Podocyturia in Fabry disease. J Bras Nefrol 2016;38:49-53. DOI
PubMed
251. Selvarajah M, Nicholls K, Hewitson TD, Becker GJ. Targeted urine microscopy in Anderson-Fabry disease: a cheap, sensitive and
specific diagnostic technique. Nephrol Dial Transplant 2011;26:3195-202. DOI PubMed
252. Trimarchi H, Canzonieri R, Schiel A, et al. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients. J
Nephrol 2016;29:791-7. DOI
253. Politei J, Alberton V, Amoreo O, et al. Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease:
is a correlation possible? Pediatr Nephrol 2018;33:2095-101. DOI PubMed
254. Liern M, Collazo A, Valencia M, et al. Podocyturia in pediatric patients with Fabry disease. Nefrología 2019;39:177-83. DOI
255. Aguiar P, Azevedo O, Pinto R, et al. New biomarkers defining a novel early stage of Fabry nephropathy: a diagnostic test study. Mol
Genet Metab 2017;121:162-9. DOI
256. Aguiar P, Azevedo O, Pinto R, et al. Tubular dysfunction biomarkers in Fabry disease: better than albuminuria to identify patients at
risk of nephropathy progression. Mol Genet Metab 2018;123:S16-7. DOI
257. Vylet'al P, Hůlková H, Zivná M, et al. Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell
storage alteration and is reversible by enzyme replacement therapy. J Inherit Metab Dis 2008;31:508-17. DOI
258. Lepedda AJ, Fancellu L, Zinellu E, et al. Urine bikunin as a marker of renal impairment in Fabry's disease. Biomed Res Int
2013;2013:205948. DOI PubMed PMC
259. Moore DF, Krokhin OV, Beavis RC, et al. Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify
biological abnormalities. Proc Natl Acad Sci USA 2007;104:2873-8. DOI PubMed PMC
260. Heo SH, Kang E, Kim YM, et al. Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy.
J Med Genet 2017;54:771-80. DOI PubMed PMC
261. Hollander Z, Dai DL, Putko BN, et al. Gender-specific plasma proteomic biomarkers in patients with Anderson-Fabry disease. Eur J
Heart Fail 2015;17:291-300. DOI
262. Cammarata G, Scalia S, Colomba P, et al. A pilot study of circulating microRNAs as potential biomarkers of Fabry disease.
Oncotarget 2018;9:27333-45. DOI PubMed PMC
263. Jaurretche S, Perez G, Antongiovanni N, Perretta F, Venera G. Variables associated with a urinary MicroRNAs excretion profile
indicative of renal fibrosis in Fabry disease patients. Int J Chronic Dis 2019;2019:4027606. DOI PubMed PMC
264. Nowak A, Haddad G, Kistler AD, et al. Circular RNA-based biomarkers in blood of patients with Fabry disease and related
phenotypes. J Med Genet 2022;59:279-86. DOI